What caused the ABT.SW stock drop today?

The ABT.SW stock decline to **CHF88.00** reflects a sharp intraday re-rating, oversold technicals (RSI **14.95**), and light volume at **10.00** shares. Market reactions ahead of the 15 Apr 2026 earnings date and sector moves likely amplified the sell-off.

What is Meyka AI's price outlook for ABT.SW stock?

Meyka AI's forecast model projects a 12-month price of **CHF100.11**, implying **+12.86%** from **CHF88.00**. The model also shows a quarterly point at **CHF129.29** and a monthly estimate **CHF50.62**. Forecasts are model projections and not guarantees.

Is ABT.SW stock a buy after the intraday sell-off?

Meyka AI assigns ABT.SW a **B+** grade and Suggestion: **BUY**, but this is informational only. With a PE of **30.45**, dividend yield near **2.20%**, and oversold technicals, consider risk controls and await earnings or clearer sector signals before adding size.

Which price levels should traders watch for ABT.SW stock?

Traders should watch support near **CHF85.00** and resistance near **CHF95.00**, with a conservative stop under **CHF84.00** on short-term positions. Liquidity is thin intraday, so execution risk is elevated.

CH Stocks

ABT.SW stock intraday: CHF88.00 falls 12.00% on SIX, analysts watch support

ByHuzaifa Zahoor March 2, 2026

ABT.SW stock opened sharply lower intraday on 02 Mar 2026, trading at CHF88.00 after a 12.00% drop from a previous close of CHF100.00 on the SIX Swiss exchange. The slide makes Abbott Laboratories one of the top losers in the Healthcare sector today in Switzerland. Key fundamentals still show an EPS of CHF2.89 and a PE of 30.45, while volume is light at 10.00 shares so far. Meyka AI, an AI-powered market analysis platform, flags oversold technicals and mixed valuation signals as catalysts to watch.